Literature DB >> 12382073

Effects of OR-1896, a metabolite of levosimendan, on force of contraction and Ca2+ transients under acidotic condition in aequorin-loaded canine ventricular myocardium.

Reiko Takahashi1, Masao Endoh.   

Abstract

We performed experiments in canine ventricular trabeculae loaded with aequorin to elucidate the influence of acidosis on the positive inotropic effect (PIE) of OR-1896 (R)- N-[4-(4-methyl-6-oxo-1,4,5,6-tetrahydro-pyridazin-3-yl)-phenyl]-acetamide, an active metabolite of levosimendan. The concentration-response curve (CRC) for OR-1896 was biphasic in acidotic conditions (pH(o) 6.6) that was essentially the same as that in control conditions (pH(o) 7.4). The CRC for PIE of OR-1896 reached a plateau at 10(-6) M (first phase) and it became steeper again at 10(-3) M (second phase). Under acidotic conditions the efficacy of the first phase was 10% of the maximal response to isoproterenol (ISO(max)) and the PIE was associated with an increase in Ca(2+) transients of 2% of ISO(max) (P<0.05). The sensitivity of myofilaments to Ca(2+) ions was increased by OR-1896 in acidotic conditions, whereas the relationship of Ca(2+) transients and contractile force during an increase in elevation of the extracellular Ca(2+) concentration and during application of dihydroouabain was shifted prominently to the right in acidotic conditions. In conclusion, OR-1896 elicited a PIE due to an increase in the sensitivity of myofilaments to Ca(2+) ions even in acidotic conditions. The PIE of OR-1896 in acidotic conditions was much less than that in control conditions because the effect of the compound to induce an increase in intracellular Ca(2+) mobilization was markedly attenuated in acidotic conditions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12382073     DOI: 10.1007/s00210-002-0627-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  9 in total

1.  Fluorescence Based Characterization of Calcium Sensitizer Action on the Troponin Complex.

Authors:  William Schlecht; King-Lun Li; Dehong Hu; Wenji Dong
Journal:  Chem Biol Drug Des       Date:  2015-09-16       Impact factor: 2.817

2.  The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles.

Authors:  Nóra Erdei; Zoltán Papp; Piero Pollesello; István Edes; Zsolt Bagi
Journal:  Br J Pharmacol       Date:  2006-05-22       Impact factor: 8.739

3.  Effects of levosimendan and dobutamine in experimental acute endotoxemia: a preliminary controlled study.

Authors:  Arnaldo Dubin; Gastón Murias; Juan Pablo Sottile; Mario Omar Pozo; Marcelo Barán; Vanina Siham Kanoore Edul; Héctor Saúl Canales; Graciela Etcheverry; Bernardo Maskin; Elisa Estenssoro
Journal:  Intensive Care Med       Date:  2007-01-30       Impact factor: 17.440

4.  Dual regulation of myofilament Ca2+ sensitivity by levosimendan in normal and acidotic conditions in aequorin-loaded canine ventricular myocardium.

Authors:  Reiko Takahashi; Masao Endoh
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

5.  Levosimendan and its metabolite OR-1896 elicit KATP channel-dependent dilation in resistance arteries in vivo.

Authors:  Ildikó Gödény; Piero Pollesello; István Edes; Zoltán Papp; Zsolt Bagi
Journal:  Pharmacol Rep       Date:  2013       Impact factor: 3.024

6.  Effects of the calcium sensitizer OR-1896, a metabolite of levosimendan, on post-infarct heart failure and cardiac remodelling in diabetic Goto-Kakizaki rats.

Authors:  Marjut Louhelainen; Saara Merasto; Piet Finckenberg; Erik Vahtola; Petri Kaheinen; Jouko Levijoki; Eero Mervaala
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

7.  Effects of Ca2+ -sensitizers in permeabilized cardiac myocytes from donor and end-stage failing human hearts.

Authors:  Z Papp; J Van Der Velden; A Borbély; I Edes; G J M Stienen
Journal:  J Muscle Res Cell Motil       Date:  2004       Impact factor: 2.698

8.  The inotropic effect of the active metabolite of levosimendan, OR-1896, is mediated through inhibition of PDE3 in rat ventricular myocardium.

Authors:  Øivind Ørstavik; Ornella Manfra; Kjetil Wessel Andressen; Geir Øystein Andersen; Tor Skomedal; Jan-Bjørn Osnes; Finn Olav Levy; Kurt Allen Krobert
Journal:  PLoS One       Date:  2015-03-04       Impact factor: 3.240

9.  Does levosimendan act as a Ca2+ sensitizer or PDE3 inhibitor?: Commentary on Orstavik et al., Br J Pharmacol 171: 5169-5181.

Authors:  Masao Endoh
Journal:  Br J Pharmacol       Date:  2015-09       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.